BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study - Turpie, AG; Fisher, WD; Bauer, KA (J Thromb Haemost, 2005)
et al.